Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAnDEM: Herceptin plus Arimidex in HER2+/HR+ Metastatic Breast Cancer
NCT00022672Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2001
- Primary completion
- Oct 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of trastuzumab in breast cancer, sponsored by Roche. Started Jan 2001; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00022672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022672.